← Back to home

REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC)

Clinical trials for REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC) explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC) trials appear

Sign up with your email to follow new studies for REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for hard-to-treat colorectal cancer: triple therapy enters phase 2 trial

Disease control Recruiting now

This study tests a new oral drug (SR-8541A) combined with two immunotherapy drugs for people with advanced colorectal cancer that has spread and no longer responds to standard chemotherapy. The trial aims to find the best dose and check if the combination is safe and effective. A…

Matched conditions: REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC)

Phase: PHASE2 • Sponsor: Stingray Therapeutics • Aim: Disease control

Last updated May 18, 2026 07:20 UTC

REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC)

Get alerted when new REFRACTORY METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS-CRC) trials appear

New hope for hard-to-treat colorectal cancer: triple therapy enters phase 2 trial